Herantis Pharma Oyj

HRTIS.HE exhibits a capital structure marked by significant leverage and negative equity. The company's debt-to-equity ratio is -2.04, indicating that liabilities exceed equity by a wide margin. Liquidity is constrained, with cash and equivalents of EUR 751,000 against total liabilities of EUR 4,356,040. The current ratio of 2.92 suggests the company can cover its short-term obligations, but the negative net cash position after subtracting total debt raises concerns about long-term solvency.

Profitability metrics are weak, with a return on equity (ROE) of 3.92% and a return on assets (ROA) of -2.48%. These figures indicate that the company is not generating sufficient returns to cover its cost of capital, and is in fact losing value on its asset base. The operating loss of EUR 6,395,570 and net loss of EUR 6,620,150 further underscore the company's unprofitable operations.

The company's revenue is reported as EUR 0, suggesting either a reporting anomaly or a complete absence of revenue generation. This is a critical red flag for a business in the pharmaceutical and medical research sector, where revenue is typically derived from product sales, licensing, or research grants. There is no segment or geographic breakdown provided, making it difficult to assess the company's exposure to different markets or product lines.

Looking ahead, the company is expected to remain unprofitable, with no clear path to revenue generation. The operating cash flow of -EUR 6,095,330 indicates that the company is not generating positive cash from operations, which is essential for sustaining operations and funding growth. The risk assessment highlights liquidity as a medium concern, with dilution risk rated as low. However, the negative net cash position after subtracting total debt is a key flag that could lead to further dilution or restructuring.

Recent analyst estimates suggest a mean price target of EUR 2.40, with a median and high target also at EUR 2.40. The mean recommendation is 2.00, indicating a "buy" rating, but there are no strong-buy recommendations, and only one buy recommendation is recorded. There are no recent filings or transcripts provided to assess management commentary or strategic direction.

The company's market capitalization of EUR 48,671,530.34 is modest, and the market price of EUR 2.02 is below the analyst price targets. The EV/EBITDA ratio of -8.03 is negative, reflecting the company's unprofitable status and lack of earnings.